REGMF (RemeGen Co) Beneish M-Score: -1.54 (As of Jun. 26, 2026)


REGMF RemeGen Co Ltd REGMF
41 GF Score
Price $12.05
GF Value $31.89
Valuation Possible Value Trap
! 6 Warning Signs
View Full Analysis

What is RemeGen Co Beneish M-Score?

RemeGen Co REGMF -6.23% 41 Beneish M-Score is -1.54 as of Jun. 26, 2026. GuruFocus rates REGMF with a GF Score™ of 41/100 and a GF Value™ of $31.89 (Possible Value Trap). The stock has 6 warning signs investors should review. Among 831 Biotechnology companies, RemeGen Co ranks worse than 71% on this metric.

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Warning Sign:

Beneish M-Score -1.54 higher than -1.78, which implies that the company might have manipulated its financial results.

The historical rank and industry rank for RemeGen Co's Beneish M-Score or its related term are showing as below:

REGMF' s Beneish M-Score Range Over the Past 10 Years
Min: -2.65   Med: -2.1   Max: -1.54
Current: -1.54

During the past 8 years, the highest Beneish M-Score of RemeGen Co was -1.54. The lowest was -2.65. And the median was -2.10.

RemeGen Co Beneish M-Score Historical Data

* Premium members only.

The historical data trend for RemeGen Co's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

RemeGen Co Beneish M-Score Chart

RemeGen Co Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beneish M-Score
Get a 7-Day Free Trial 0.00 0.00 0.00 -2.65 -1.54

RemeGen Co Quarterly Data
Dec18 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Jun25 Sep25 Dec25
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.40 -2.65 -3.53 -2.19 -1.54

REGMF vs VRTX, REGN, ALNY: Beneish M-Score Comparison

For the Biotechnology subindustry, RemeGen Co's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

RemeGen Co Beneish M-Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, RemeGen Co's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where RemeGen Co's Beneish M-Score falls into.


REGMF
41GF Score
RemeGen Co Ltd REGMF
Beneish M-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

RemeGen Co Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of RemeGen Co for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 0.8221+0.528 * 0.91+0.404 * 0.6512+0.892 * 1.7634+0.115 * 1
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 0.5947+4.679 * 0.107114-0.327 * 0.8599
=-1.53

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec25) TTM:Last Year (Sep24) TTM:
Total Receivables was $115.2 Mil.
Revenue was 216.056 + 88.139 + 0 + 68.85 = $373.0 Mil.
Gross Profit was 194.062 + 74.036 + 0 + 55.383 = $323.5 Mil.
Total Current Assets was $565.4 Mil.
Total Assets was $1,029.1 Mil.
Property, Plant and Equipment(Net PPE) was $421.7 Mil.
Depreciation, Depletion and Amortization(DDA) was $0.0 Mil.
Selling, General, & Admin. Expense(SGA) was $170.3 Mil.
Total Current Liabilities was $396.5 Mil.
Long-Term Debt & Capital Lease Obligation was $106.8 Mil.
Net Income was 178.946 + -14.197 + 0 + -54.519 = $110.2 Mil.
Non Operating Income was 0 + 0 + 0 + 0 = $0.0 Mil.
Cash Flow from Operations was 0 + 0 + 0 + 0 = $0.0 Mil.
 Total Receivables was $79.5 Mil.
Revenue was 66.311 + 56.408 + 45.884 + 42.948 = $211.6 Mil.
Gross Profit was 55.645 + 43.325 + 35.559 + 32.397 = $166.9 Mil.
Total Current Assets was $356.7 Mil.
Total Assets was $807.3 Mil.
Property, Plant and Equipment(Net PPE) was $400.0 Mil.
Depreciation, Depletion and Amortization(DDA) was $0.0 Mil.
Selling, General, & Admin. Expense(SGA) was $162.4 Mil.
Total Current Liabilities was $263.0 Mil.
Long-Term Debt & Capital Lease Obligation was $196.1 Mil.

1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(115.249 / 373.045) / (79.504 / 211.551)
=0.308941 / 0.375815
=0.8221

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(166.926 / 211.551) / (323.481 / 373.045)
=0.789058 / 0.867137
=0.91

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (565.352 + 421.685) / 1029.088) / (1 - (356.7 + 399.978) / 807.336)
=0.040862 / 0.062747
=0.6512

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=373.045 / 211.551
=1.7634

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(0 / (0 + 399.978)) / (0 / (0 + 421.685))
=0 / 0
=1

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(170.32 / 373.045) / (162.413 / 211.551)
=0.456567 / 0.767725
=0.5947

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((106.755 + 396.457) / 1029.088) / ((196.13 + 262.972) / 807.336)
=0.488988 / 0.568663
=0.8599

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(110.23 - 0 - 0) / 1029.088
=0.107114

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

RemeGen Co has a M-score of -1.53 signals that the company is likely to be a manipulator.

Frequently Asked Questions Learn more about Beneish M-Score →
What does a Beneish M-Score of -1.54 mean?
RemeGen Co (REGMF) has a Beneish M-Score of -1.54 as of Jun. 26, 2026. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on RemeGen Co and its competitors. According to the industry distribution chart, RemeGen Co ranks #590 out of 831 companies in the Biotechnology industry, placing it in the top 71%.
Is RemeGen Co's Beneish M-Score too high?
RemeGen Co's current Beneish M-Score is -1.54. Based on the distribution chart, RemeGen Co ranks #590 out of 831 companies in the Biotechnology industry, which is below the industry midpoint. Overall, RemeGen Co has a GF Score™ of 41/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does RemeGen Co's Beneish M-Score compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, RemeGen Co ranks #590 out of 831 companies for Beneish M-Score. This places RemeGen Co in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beneish M-Score for a Biotechnology company?
A good Beneish M-Score depends on the Biotechnology industry context. However, Beneish M-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beneish M-Score mean?
A high Beneish M-Score can signal that a stock is expensive relative to its fundamentals. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on RemeGen Co and its competitors. RemeGen Co's current Beneish M-Score is -1.54. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is RemeGen Co stock overvalued right now?
Based on GuruFocus' analysis, RemeGen Co (REGMF) is currently considered Possible Value Trap. The stock's GF Value™ is $31.89, compared to a current price of $12.05 — trading 62.2% below its estimated fair value. The current Beneish M-Score is -1.54. RemeGen Co's overall GF Score™ is 41/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beneish M-Score calculated?
Beneish M-Score is calculated from a company's financial statements. For RemeGen Co (REGMF), the current Beneish M-Score is -1.54 as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is RemeGen Co (REGMF) Overvalued in 2026?

Based on GuruFocus' analysis, RemeGen Co stock appears to be undervalued. The current stock price of $12.05 is trading 62.2% below its estimated GF Value™ of $31.89. GuruFocus considers RemeGen Co to be Possible Value Trap.

Key valuation signals for REGMF:

  • Beneish M-Score: -1.54
  • GF Value™: $31.89 vs. price of $12.05 (62.2% below fair value)
  • GF Score™: 41/100 with 6 warning signs

No single metric tells the full story. See the REGMF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

RemeGen Co Business Description

Address 58 Middle Beijing Road, Yantai Area of Shandong Pilot Free Trade Zone, Yantai Development Zone, Yantai, CHN
RemeGen Co Ltd is a China-based company mainly engaged in the research, development and manufacture of biopharmaceuticals. The company offers Telitacicept (RC18) for use in the treatment of systemic lupus erythematosus an autoimmune disease and Disitamab Vedotin (RC48) for use in the treatment of various cancers. The company's products are mainly used to treat severe diseases such as autoimmune diseases, oncology, and ophthalmology. It has its operations in China and the USA and derives the majority of its revenue from China.
41GF Score

Get the complete analysis for REGMF

Beneish M-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$12.05
Price
$31.89
GF Value